Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase III clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois.
Market Trend Signal
Stock Analysis Software and Trading System